Literature DB >> 31814913

lncRNA PCAT-1 interacting with FZD6 contributes to the malignancy of acute myeloid leukemia cells through activating Wnt/β-catenin signaling pathway.

Yuan Yuan1, Qian Wang2, Shu Li Ma1, Long Qiang Xu1, Meng Yang Liu1, Bin Han1, Ning Du1, Xiao Lan Sun1, Xiao Lin Yin1, Fang Fang Cao1.   

Abstract

Accumulating evidence has suggested the involvement of long noncoding RNAs (lncRNAs) on the acute myeloid leukemia (AML). Therefore, this study aimed to investigate the unknown function of lncRNA Prostate cancer-associated transcript-1 (PCAT-1) in AML cells. Our data found that PCAT-1 was highly expressed in AML-M1/2 and AML-M3 patients than normal controls and its expression was significantly up-regulated in AML cell lines Kasumi-6 and HL-60. The functional experiments demonstrated that knockdown of PCAT-1 remarkably inhibited proliferation, arrested cell cycle progression and triggered apoptosis of AML cells. Mechanistically, we revealed that PCAT-1 could directly interact with FZD6 protein to regulate its stability. Overexpression of FZD6 partly abolished the effects of PCAT-1 silencing on AML cells. Our integrated experiments then suggested that PCAT-1 could activate the Wnt/β-catenin signaling pathway in an FZD6-dependent manner. Taken together, the present study indicated that PCAT-1 interacting with FZD6 to activate Wnt/β-catenin signaling, which may play an important role in the pathogenesis of AML. AJTR
Copyright © 2019.

Entities:  

Keywords:  Acute myeloid leukemia; FZD6; PCAT-1; Wnt/β-catenin signaling

Year:  2019        PMID: 31814913      PMCID: PMC6895506     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  25 in total

Review 1.  PCAT-1: A pivotal oncogenic long non-coding RNA in human cancers.

Authors:  Zhi Yang; Shan Zhao; Xiangyu Zhou; Haiying Zhao; Xiaofeng Jiang
Journal:  Biomed Pharmacother       Date:  2018-12-06       Impact factor: 6.529

2.  TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2.

Authors:  Qun Li; Wei Song; Jianmin Wang
Journal:  Biomed Pharmacother       Date:  2018-11-26       Impact factor: 6.529

3.  Competitive balance of intrabulge BMP/Wnt signaling reveals a robust gene network ruling stem cell homeostasis and cyclic activation.

Authors:  Eve Kandyba; Yvonne Leung; Yi-Bu Chen; Randall Widelitz; Cheng-Ming Chuong; Krzysztof Kobielak
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-04       Impact factor: 11.205

Review 4.  Wnts and Hedgehogs: lipid-modified proteins and similarities in signaling mechanisms at the cell surface.

Authors:  Roel Nusse
Journal:  Development       Date:  2003-11       Impact factor: 6.868

5.  Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression.

Authors:  John R Prensner; Matthew K Iyer; O Alejandro Balbin; Saravana M Dhanasekaran; Qi Cao; J Chad Brenner; Bharathi Laxman; Irfan A Asangani; Catherine S Grasso; Hal D Kominsky; Xuhong Cao; Xiaojun Jing; Xiaoju Wang; Javed Siddiqui; John T Wei; Daniel Robinson; Hari K Iyer; Nallasivam Palanisamy; Christopher A Maher; Arul M Chinnaiyan
Journal:  Nat Biotechnol       Date:  2011-07-31       Impact factor: 54.908

Review 6.  Non-canonical WNT/PCP signalling in cancer: Fzd6 takes centre stage.

Authors:  G Corda; A Sala
Journal:  Oncogenesis       Date:  2017-07-24       Impact factor: 7.485

7.  A Deep Learning Framework for Robust and Accurate Prediction of ncRNA-Protein Interactions Using Evolutionary Information.

Authors:  Hai-Cheng Yi; Zhu-Hong You; De-Shuang Huang; Xiao Li; Tong-Hai Jiang; Li-Ping Li
Journal:  Mol Ther Nucleic Acids       Date:  2018-03-09       Impact factor: 8.886

8.  Long non-coding RNA PCAT-1 promotes tumor progression by inhibiting miR-129-5p in human ovarian cancer.

Authors:  Li-Ping Gu; Shuo Jin; Rong-Chun Xu; Jing Zhang; Ying-Chun Geng; Xing-Yue Shao; Li-Bo Qin
Journal:  Arch Med Sci       Date:  2018-04-30       Impact factor: 3.318

9.  NPTX2 promotes colorectal cancer growth and liver metastasis by the activation of the canonical Wnt/β-catenin pathway via FZD6.

Authors:  Chunjie Xu; Guangang Tian; Chunhui Jiang; Hanbing Xue; Manzila Kuerbanjiang; Longci Sun; Lei Gu; Hong Zhou; Ye Liu; Zhigang Zhang; Qing Xu
Journal:  Cell Death Dis       Date:  2019-03-04       Impact factor: 8.469

Review 10.  Aberrant lncRNA Expression in Multiple Myeloma.

Authors:  Hui Meng; Lei Han; Chun Hong; Jinya Ding; Qianchuan Huang
Journal:  Oncol Res       Date:  2017-12-04       Impact factor: 5.574

View more
  4 in total

1.  Construction of Fzd6Q152E mice through CRISPR/Cas9 technology and their reproduction and identification.

Authors:  Xiaoru Yan; Junting Yang; Lanfei Xiao; Jiping Gao; Guoqiang Xu; Liang Wang; Yang Qi; Guohua Song
Journal:  Mol Biol Rep       Date:  2022-08-18       Impact factor: 2.742

2.  MicroRNA-935 Directly Targets FZD6 to Inhibit the Proliferation of Human Glioblastoma and Correlate to Glioma Malignancy and Prognosis.

Authors:  Dainan Zhang; Shunchang Ma; Chuanbao Zhang; Peiliang Li; Beibei Mao; Xiudong Guan; Wenjianlong Zhou; Jiayi Peng; Xi Wang; Shaomin Li; Wang Jia
Journal:  Front Oncol       Date:  2021-03-12       Impact factor: 6.244

3.  The Prognostic Value of the Developmental Gene FZD6 in Young Saudi Breast Cancer Patients: A Biomarkers Discovery and Cancer Inducers OncoScreen Approach.

Authors:  Mourad Assidi; Abdelbaset Buhmeida; Maryam H Al-Zahrani; Jaudah Al-Maghrabi; Mahmood Rasool; Muhammad I Naseer; Heba Alkhatabi; Abdulmajeed F Alrefaei; Ali Zari; Razan Elkhatib; Adel Abuzenadah; Peter N Pushparaj; Muhammad Abu-Elmagd
Journal:  Front Mol Biosci       Date:  2022-02-14

4.  WNT7A Promotes EGF-Induced Migration of Oral Squamous Cell Carcinoma Cells by Activating β-Catenin/MMP9-Mediated Signaling.

Authors:  Hui Xie; Yadong Ma; Jun Li; Huixia Chen; Yongfu Xie; Minzhen Chen; Xuyang Zhao; Sijie Tang; Shuo Zhao; Yujie Zhang; Jun Du; Feimin Zhang; Luo Gu
Journal:  Front Pharmacol       Date:  2020-02-26       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.